Result of AGM

Futura Medical PLC

20 June 2024

 

20 June 2024

Futura Medical plc

("Futura", "the Group" or the "Company")

Result of AGM

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, today announces that at its Annual General Meeting, held today at 10:00am BST, the shareholders duly passed all resolutions.

The total number of votes received on each resolution were as follows:

		Voting For		Voting Against
		Number of votesi	%	Number of votes	%	Total Votes	% ISC	Votes withheldii
Resolution 1	To receive and adopt the annual report and accounts for the financial year ended 31 December 2023	145,896,305	99.50	738,451	0.50	146,634,756	48.57	121,536
Resolution 2	That Roy Davis be and is hereby appointed as a Director of the Company.	146,637,030	99.98	30,544	0.02	146,667,574	48.58	91,718
Resolution 3	To re-elect Angela Hildreth as a Director of the Company, who retires by rotation in accordance with the Company's articles of association.	146,583,928	99.94	80,896	0.06	146,664,824	48.58	91,468
Resolution 4	To re-appoint Grant Thornton UK LLP as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company.	146,559,436	99.95	74,813	0.05	146,634,249	48.57	122,043
Resolution 5	To authorise the Directors to determine the remuneration of Grant Thornton UK LLP as auditor of the Company	146,544,066	99.95	68,860	0.05	146,612,926	48.56	143,366
Resolution 6	That the Directors are generally and unconditionally authorised for the purposes of section 551 Companies Act 2006 (the "CA 2006") to exercise all the powers of the Company to allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company.	146,000,585	99.50	735,009	0.50	146,735,594	48.60	20,698
Resolution 7iii	Disapplication of pre-emption rights	145,446,404	99.13	1,279,733	0.87	146,726,137	48.60	30,155
Resolution 8 iii	Disapplication of pre-emption rights in respect of an additional 20% of the company issued share capital	146,060,258	99.54	669,879	0.46	146,730,137	48.60	26,155

ⁱ Where shareholders appointed the Chairman as their proxy with discretion as to voting, their votes were cast in favour of the resolution

ⁱⁱ A vote withheld is not a vote in law and is not counted towards the votes cast "For" or "Against" a resolution

ⁱⁱⁱ Special Resolution (75% majority required)

The total voting rights of the Company as at 10:00 am on 18 June 2024 (the time by which shareholders wanting to vote at the AGM were required to be entered on the register) was 301,863,641 ordinary shares of 0.2p each. The Company does not hold any shares in treasury.

Contacts:

Futura Medical plc	James Barder Chief Executive Officer Angela Hildreth Finance Director and COO	[e-mail] [phone] www.futuramedical.com
Liberum Nominated Adviser and Broker	Richard Lindley Nikhil Varghese	[phone]
Stifel Nicolaus Europe Limited Joint Broker	Alan Selby Ben Maddison	[phone]
Alma Strategic Communications	Rebecca Sanders-Hewett Sam Modlin Will Ellis Hancock	[phone] [e-mail]

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.

 

END